S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
S&P 500   3,128.21 (-3.03%)
DOW   27,081.36 (-3.15%)
QQQ   215.37 (-2.72%)
AAPL   288.08 (-3.39%)
FB   196.77 (-1.97%)
MSFT   168.07 (-1.65%)
GOOGL   1,386.32 (-2.36%)
AMZN   1,972.74 (-1.82%)
CGC   19.62 (-3.35%)
NVDA   262.05 (-4.11%)
BABA   205.61 (-0.27%)
MU   52.10 (-5.29%)
GE   11.32 (-4.55%)
TSLA   799.91 (-4.06%)
AMD   47.57 (-3.16%)
T   37.35 (-1.84%)
ACB   1.51 (-2.58%)
F   7.23 (-4.49%)
NFLX   360.09 (-2.34%)
PRI   121.42 (-4.37%)
BAC   31.08 (-5.04%)
DIS   128.19 (-3.62%)
GILD   70.10 (-3.84%)
Log in

NASDAQ:ONVO - Organovo Stock Price, Forecast & News

$0.31
-0.02 (-6.06 %)
(As of 02/25/2020 04:00 PM ET)
Today's Range
$0.31
Now: $0.31
$0.34
50-Day Range
$0.29
MA: $0.37
$0.49
52-Week Range
$0.22
Now: $0.31
$1.17
Volume250,480 shs
Average Volume561,770 shs
Market Capitalization$40.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
Organovo Holdings, Inc, a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.09 million
Book Value$0.30 per share

Profitability

Net Income$-26,640,000.00
Net Margins-798.68%

Miscellaneous

Employees70
Market Cap$40.49 million
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.


Organovo (NASDAQ:ONVO) Frequently Asked Questions

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

How were Organovo's earnings last quarter?

Organovo Holdings Inc (NASDAQ:ONVO) announced its earnings results on Thursday, August, 8th. The medical research company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). The medical research company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.77 million. Organovo had a negative net margin of 798.68% and a negative return on equity of 69.36%. View Organovo's Earnings History.

When is Organovo's next earnings date?

Organovo is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Organovo.

What is the consensus analysts' recommendation for Organovo?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organovo in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Organovo.

Has Organovo been receiving favorable news coverage?

Headlines about ONVO stock have been trending very negative on Tuesday, according to InfoTrie. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organovo earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Organovo.

Are investors shorting Organovo?

Organovo saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,580,000 shares, an increase of 6.8% from the January 15th total of 1,480,000 shares. Based on an average trading volume of 726,000 shares, the short-interest ratio is currently 2.2 days. Currently, 1.2% of the company's shares are short sold. View Organovo's Current Options Chain.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

Who are Organovo's key executives?

Organovo's management team includes the folowing people:
  • Mr. Taylor J. Crouch, CEO, Pres & Director (Age 59)
  • Mr. Craig Kussman, Chief Financial Officer (Age 60)
  • Ms. Jennifer Kinsbruner Bush, Sr. VP, Compliance Officer, Gen. Counsel & Corp. Sec. (Age 44)
  • Mr. Paul Gallant, Gen. Mang. (Age 54)
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications

Who are Organovo's major shareholders?

Organovo's stock is owned by many different of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (14.95%), Renaissance Technologies LLC (5.38%), Essex Investment Management Co. LLC (1.01%) and UBS Group AG (0.07%). View Institutional Ownership Trends for Organovo.

Which major investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Organovo.

Which major investors are buying Organovo stock?

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Renaissance Technologies LLC and ARK Investment Management LLC. View Insider Buying and Selling for Organovo.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $0.31.

How big of a company is Organovo?

Organovo has a market capitalization of $40.49 million and generates $3.09 million in revenue each year. The medical research company earns $-26,640,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis. Organovo employs 70 workers across the globe.View Additional Information About Organovo.

What is Organovo's official website?

The official website for Organovo is http://www.organovo.com/.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


MarketBeat Community Rating for Organovo (NASDAQ ONVO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  366
MarketBeat's community ratings are surveys of what our community members think about Organovo and other stocks. Vote "Outperform" if you believe ONVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel